IL18 and myeloid sarcoma: MR results (Supplemental Figures 3 and 4) did not support the causal effect of IL-18 on MS risk (OR, 0.85; 95% CI, 0.66–1.10; p = 0.216), and there was no significant heterogeneity (Q =0.01, p =0.976).